welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)

key information

study id #: NCT02808585

condition: Heart Failure

status: completed


This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in subsequent cohorts. Randomized subjects will receive a fixed weekly dose of study drug or placebo for a 4 week dosing period.

intervention: PB1046 Injection, Placebo Injection

mechanism of action: Vasoactive intestinal pepetide (VIP) receptor agonist to prevent cardiac function deterioration

results: https://clinicaltrials.gov/ct2/show/results/NCT02808585

last updated: October 21, 2019